C urrent neuropathologic examination of the brain is still the gold standard for diagnosis of Alzheimer's disease (AD). Postmortem studies, however, have indicated that current methods for the clinical diagnosis of AD are suboptimal. 1 Recent research has demonstrated the clinical utility of amyloid-beta positron emission tomography (PET) scans, which detect the presence of amyloid-beta plaques in the brain. In a study presented at the Alzheimer's Association International Conference (AAIC) in London, UK, July 2017, by Nenad Bogdanovic, MD, PhD, of the University of Oslo in Norway, amyloid PET imaging was found to be a fundamental diagnostic tool for AD, establishing a definite diagnosis or excluding AD in all 50 study participants. 2 The use of cerebrospinal fluid (CSF) amyloid testing with a higher amyloid-beta plaque threshold than that traditionally used to establish a positive finding also resulted in high diagnostic accuracy, resulting in diagnosis or exclusion in 44 of 50 participants (88%) compared with only 21 individuals (42%) using traditional cutoffs. 2 In an expert interview following AAIC 2017, Dr. Bogdanovic discusses the challenges of diagnosing AD and future developments in this active area of research.
Q. Why is the diagnosis of Alzheimer's disease (AD) so challenging?
It is relatively easy to make a diagnosis of dementia, but to determine AD at an early stage is still a clinical challenge. AD is considered as a patho-clinical continuum where neuropathological changes start to accumulate in the brain probably 10-15 years before the first sign of clinical impairment. 
Q. What methods are currently under investigation?
Methods specifically directed to AD biomarkers such as PET-amyloid, Q. Among these, which do you consider most promising and why?
Tau imaging is the most promising method currently under investigation and is close to gaining acceptance for routine clinical use. Once a PET-tau ligand is accepted by regulatory authorities we would be able to visualize the two most important AD pathological hallmarks, which will allow not only a very precise analysis of disease staging, but will also help clinicians in differential diagnoses against other dementia disorders. Blood biomarkers are also a highly promising approach but still require further development.
Q. What other blood-based biomarkers are being evaluated for AD?
The challenge with blood-based biomarkers is failure to replicate findings preventing widespread acceptance of any blood-based assay for AD. Blood is very complex, characterized by multiple cellular compartments and an ever-changing environment of proteins, lipids, and other biochemical entities that affect standardization and reproducibility of results. Specifically, participant's age, cognitive health of subjects, diet of the participants, the assay used, inter-lab variability and little correspondence with clinical stage are some of the major obstacles that should be resolved. Recently some other Aβ species, particularly Aβ 1-17 , have been proposed to be useful for the diagnosis of AD. 6 Neurofilament light chain protein also appears to be a promising marker of disease in preclinical studies of AD, 7 and its elevation in CSF may help in making differential diagnoses of some genetic forms of frontal lobe dementia. 8 
